Teva Pharmaceutical Industries Limited (TEVA) PT Set at $17.00 by Cantor Fitzgerald

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been given a $17.00 price target by equities researchers at Cantor Fitzgerald in a note issued to investors on Monday. The brokerage currently has a “hold” rating on the stock. Cantor Fitzgerald’s price target would suggest a potential downside of 12.05% from the stock’s previous close.

Several other equities research analysts also recently commented on TEVA. Jefferies Group LLC restated a “hold” rating and issued a $26.00 price target (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and issued a $28.00 target price (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Sanford C. Bernstein downgraded shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $42.00 to $28.00 in a research report on Friday, August 4th. Maxim Group reiterated a “hold” rating and issued a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, July 13th. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $39.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Five analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $32.65.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 19.33 on Monday. The firm has a 50-day moving average price of $20.60 and a 200 day moving average price of $28.94. The firm’s market capitalization is $19.64 billion. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $52.66.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm’s revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.25 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Limited (TEVA) PT Set at $17.00 by Cantor Fitzgerald” was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.thestockobserver.com/2017/09/13/teva-pharmaceutical-industries-limited-teva-pt-set-at-17-00-by-cantor-fitzgerald.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of TEVA. Capital Research Global Investors grew its position in Teva Pharmaceutical Industries Limited by 13.8% in the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after purchasing an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. grew its position in Teva Pharmaceutical Industries Limited by 11.1% in the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after purchasing an additional 6,685,844 shares during the last quarter. FMR LLC grew its position in Teva Pharmaceutical Industries Limited by 16.7% in the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares during the last quarter. Capital World Investors grew its position in Teva Pharmaceutical Industries Limited by 41.9% in the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after purchasing an additional 3,268,200 shares during the last quarter. Finally, Alliancebernstein L.P. grew its position in Teva Pharmaceutical Industries Limited by 32.3% in the 2nd quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock worth $378,688,000 after purchasing an additional 2,782,257 shares during the last quarter. Institutional investors own 56.87% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply